stockportfolio.pro
Stocks / DHR vs PFE
DHR vs PFE
Danaher Corporation and Pfizer Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Danaher Corporation (DHR) | Pfizer Inc. (PFE) | |
|---|---|---|
| Market cap | $133.4B | $146.5B |
| Revenue (latest FY) | $24.57B | $62.58B |
| Net income (latest FY) | $3.61B | $7.77B |
| Revenue growth (5y CAGR) | 2.0% | 8.5% |
| Net margin | 14.7% | 12.4% |
| Return on equity | 6.9% | 9.0% |
| P/E ratio | 36.5 | 19.6 |
| Dividend yield | 0.9% | 6.7% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DHR — free Open PFE — freeFrequently asked questions
Which is bigger, DHR or PFE?
Pfizer Inc. is larger by market capitalization — $146.5B versus $133.4B.
Which grows faster, DHR or PFE?
Over the last five fiscal years, Pfizer Inc. grew revenue faster — 8.5%/yr versus 2.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.